EGFR and non-small cell lung carcinoma: Given the established role of EGFR mutations in promoting an immunosuppressive TIME (23, 24)and the limited effectiveness of immune checkpoint inhibitors (ICIs) covering anti-PD-1/PD-L1 therapies in EGFR-mutant NSCLC (25, 26), there is a pressing need to develop innovative treatment targets.